Inactive Instrument

Other languages Mindset Pharma Inc.

Equities

MSET

CA60268M1023

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Otsuka America, Inc. completed the acquisition of Mindset Pharma Inc..	23-10-26
Mindset Pharma Inc. Receives Approval for Phase II Clinical Trial Evaluating MSP-1014 for the Treatment of Major Depressive Disorder	23-06-22
Mindset Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-30
Mindset Pharma Inc. Files Two Patent Applications for its Non-Hallucinogenic Non-Tryptamine Compounds	23-04-26
Mindset Pharma Inc. and PharmAla Biotech Holdings Inc. Complete First Sale of Pharmaceutical Grade Psilocybin into Growing Australian Market Via Sales Partnership	23-03-06
Mindset Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-23
Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding Composition of Matter for Family 1 Psilocybin Analogs	23-02-02
Mindset Pharma Inc. Receives Allowance for U.S. Patent Application Covering Composition of Matter for Its Lead Psychedelic Therapeutic Candidate	23-01-20
Mindset Pharma Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	22-11-29
Mindset Pharma Inc. and Pharmala Biotech Holdings Inc. Enter into Exclusive Sales Agreement for the Sale and Distribution of Pharmaceutical Grade Psilocybin	22-11-16
Mindset Pharma Presents Poster At Neuroscience 2022 Highlighting Preclinical Data on MSP-1014, Its Psilocybin-Like Lead Drug Candidate	22-11-14
Mindset Pharma Inc. Reports Earnings Results for the Full Year Ended June 30, 2022	22-10-26
Mindset Pharma Inc. Selects Lead Clinical Candidates From “Family 2” of its Next Generation Psychedelic Drug Portfolio	22-10-05
Cybin IRL Limited Obtains Exclusive License to A Novel Catalog of Psychedelic-Based Compounds from Mindset Pharma Inc	22-09-27
Mindset Pharma Inc.: Mindset Pharma vergibt Lizenz zur strategischen Nutzung geistiger Eigentumsrechte an Cybin	22-09-27
Mindset Pharma Inc. Provides Strategic Intellectual Property License to Cybin Inc	22-09-27
Mindset Pharma Inc. Receives Scientific Advice from UK Regulator Facilitating Advancement of Phase 1 First-In-Human Clinical Trial Plan for Its Lead Clinical Candidate, MSP-1014	22-09-14
Mindset Pharma Files National Patents Protecting Family 1 Application in 16 Different Countries	22-09-07
Mindset Pharma Further Expands Its IP Portfolio with Three Additional Non-Tryptamine Families of Next-Generation Psychedelic Compounds	22-09-07
Mindset Pharma Inc. Files National Patents Protecting Family 1 Application in 16 Different Countries	22-09-07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Mindset Pharma Inc.

Equities

MSET

CA60268M1023

Other languages

Filters